The European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC): experiences from a successful ERS Clinical Research Collaboration
暂无分享,去创建一个
F. Blasi | C. Haworth | J. Chalmers | S. Aliberti | M. Loebinger | M. Crichton | L. Morgan | P. Goeminne | R. Dhar | A. De Soyza | Jeanette Boyd | M. Vendrell | E. Polverino | M. Almagro
[1] J. Chalmers,et al. “The missing ingredient”: the patient perspective of health related quality of life in bronchiectasis: a qualitative study , 2018, BMC Pulmonary Medicine.
[2] S. Marshall,et al. Neutrophil extracellular traps are associated with disease severity and microbiota diversity in patients with chronic obstructive pulmonary disease , 2018, The Journal of allergy and clinical immunology.
[3] S. Salvi,et al. Phenotype characterization of non-cystic fibrosis bronchiectasis in India , 2017 .
[4] R. Cordovilla,et al. Etiología de las bronquiectasias en una cohorte de 2.047 pacientes. Análisis del registro histórico español , 2017 .
[5] C. Olveira,et al. Etiology of Bronchiectasis in a Cohort of 2047 Patients. An Analysis of the Spanish Historical Bronchiectasis Registry. , 2017, Archivos de bronconeumologia.
[6] T. Welte,et al. Pulmonary exacerbation in adults with bronchiectasis: a consensus definition for clinical research , 2017, European Respiratory Journal.
[7] L. Dupont,et al. Bronchiectasis Rheumatoid Overlap Syndrome Is an Independent Risk Factor for Mortality in Patients With Bronchiectasis: A Multicenter Cohort Study , 2017, Chest.
[8] S. Marshall,et al. Neutrophil Elastase Activity Is Associated with Exacerbations and Lung Function Decline in Bronchiectasis , 2017, American journal of respiratory and critical care medicine.
[9] A. O'donnell,et al. Adult Patients With Bronchiectasis: A First Look at the US Bronchiectasis Research Registry , 2017, Chest.
[10] S. Sethi,et al. Raising awareness of bronchiectasis in primary care: overview of diagnosis and management strategies in adults , 2017, npj Primary Care Respiratory Medicine.
[11] G. Canonica,et al. The era of research collaborations: new models for working together , 2017, European Respiratory Journal.
[12] L. Lynd,et al. Do inhaled corticosteroids protect against lung cancer in patients with COPD? A systematic review , 2017, Respirology.
[13] H. Omran,et al. The international primary ciliary dyskinesia cohort (iPCD Cohort): methods and first results , 2017, European Respiratory Journal.
[14] J. Laffey,et al. Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort study. , 2016, The Lancet. Respiratory medicine.
[15] M. Miravitlles,et al. Prevalence and incidence of bronchiectasis in Catalonia, Spain: A population-based study. , 2016, Respiratory medicine.
[16] J. Khoo,et al. Bronchiectasis in the Last Five Years: New Developments , 2016, Journal of clinical medicine.
[17] F. Blasi,et al. Characterizing Non-Tuberculous Mycobacteria Infection in Bronchiectasis , 2016, International journal of molecular sciences.
[18] D. Obradović,et al. Characterization of bronchiectasis in the elderly. , 2016, Respiratory medicine.
[19] Siân Williams,et al. European Lung Foundation: from local to global , 2016, Breathe.
[20] J. Chalmers,et al. Global impact of bronchiectasis and cystic fibrosis , 2016, Breathe.
[21] J. Laffey,et al. Multidimensional severity assessment in bronchiectasis: an analysis of seven European cohorts , 2016, Thorax.
[22] O. Sibila,et al. Diagnostic challenges of bronchiectasis. , 2016, Respiratory medicine.
[23] J. Chalmers,et al. Research priorities in bronchiectasis: a consensus statement from the EMBARC Clinical Research Collaboration , 2016, European Respiratory Journal.
[24] M. Mantero,et al. Quality standards for the management of bronchiectasis in Italy: a national audit , 2016, European Respiratory Journal.
[25] L. Dupont,et al. The generalizability of bronchiectasis randomized controlled trials: A multicentre cohort study. , 2016, Respiratory medicine.
[26] G. Sotgiu,et al. Clinical phenotypes in adult patients with bronchiectasis , 2016, European Respiratory Journal.
[27] H. Goossens,et al. The Innovative Medicines Initiative's New Drugs for Bad Bugs programme: European public-private partnerships for the development of new strategies to tackle antibiotic resistance. , 2016, The Journal of antimicrobial chemotherapy.
[28] T. Welte,et al. The EMBARC European Bronchiectasis Registry: protocol for an international observational study , 2016, ERJ Open Research.
[29] P. Goeminne,et al. Bronchiectasis: how to be an orphan with many parents? , 2016, European Respiratory Journal.
[30] S. Lonni,et al. Bronchiectasis Rheumatoid Overlap Syndrome(BROS) is an Independent Risk Factor for Mortalityin Patients with Bronchiectasis: A Multicentre CohortStudy , 2016 .
[31] A. Torres,et al. Etiology of Non-Cystic Fibrosis Bronchiectasis in Adults and Its Correlation to Disease Severity. , 2015, Annals of the American Thoracic Society.
[32] L. Smeeth,et al. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study , 2015, European Respiratory Journal.
[33] J. Chalmers,et al. A Comprehensive Analysis of the Impact of Pseudomonas aeruginosa Colonization on Prognosis in Adult Bronchiectasis. , 2015, Annals of the American Thoracic Society.
[34] O. Sibila,et al. Secreted mucins and airway bacterial colonization in non‐CF bronchiectasis , 2015, Respirology.
[35] I. Pavord,et al. A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis , 2015, European Respiratory Journal.
[36] Andrew J. Oler,et al. Pulmonary Nontuberculous Mycobacterial Infection. A Multisystem, Multigenic Disease. , 2015, American journal of respiratory and critical care medicine.
[37] T. Welte,et al. Bronchiectasis in Germany: a population-based estimation of disease prevalence , 2015, European Respiratory Journal.
[38] P. Powell,et al. From tokenism to meaningful engagement: best practices in patient involvement in an EU project , 2015, Research Involvement and Engagement.
[39] J. Chalmers,et al. Challenges in the development of new therapies for bronchiectasis , 2015, Expert opinion on pharmacotherapy.
[40] J. Elborn,et al. Reclaiming the name ‘bronchiectasis’ , 2015, Thorax.
[41] Stefano Aliberti,et al. Management of bronchiectasis in adults , 2015, European Respiratory Journal.
[42] J. Elborn,et al. COPD–bronchiectasis overlap syndrome , 2015, European Respiratory Journal.
[43] G. Rogers,et al. The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial. , 2014, The Lancet. Respiratory medicine.
[44] F. Blasi,et al. COPD and Bronchiectasis: Phenotype, Endotype or Co-morbidity? , 2014, COPD.
[45] G. Redding,et al. Respiratory exacerbations in indigenous children from two countries with non-cystic fibrosis chronic suppurative lung disease/bronchiectasis. , 2014, Chest.
[46] P. Thompson,et al. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. , 2014, The Lancet. Respiratory medicine.
[47] D. Davidson,et al. Atorvastatin as a stable treatment in bronchiectasis: a randomised controlled trial. , 2014, The Lancet. Respiratory medicine.
[48] D. Bilton,et al. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. , 2014, American journal of respiratory and critical care medicine.
[49] Stefano Aliberti,et al. The bronchiectasis severity index. An international derivation and validation study. , 2014, American journal of respiratory and critical care medicine.
[50] S. Seys,et al. The Sputum Colour Chart as a predictor of lung inflammation, proteolysis and damage in non‐cystic fibrosis bronchiectasis: A case–control analysis , 2014, Respirology.
[51] A. Hill,et al. Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis. , 2013, Molecular immunology.
[52] Richard C Boucher,et al. Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation. , 2013, American journal of respiratory and critical care medicine.
[53] A. Hill,et al. Mannose-binding lectin deficiency and disease severity in non-cystic fibrosis bronchiectasis: a prospective study. , 2013, The Lancet. Respiratory medicine.
[54] W. Boersma,et al. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial. , 2013, JAMA.
[55] N. Karalus,et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial , 2012, The Lancet.
[56] D Bilton,et al. British Thoracic Society guideline for non-CF bronchiectasis , 2010, Thorax.
[57] M. Macek,et al. Comparative demographics of the European cystic fibrosis population: a cross-sectional database analysis , 2010, The Lancet.
[58] R. Coll,et al. Diagnóstico y tratamiento de las bronquiectasias , 2008 .
[59] M. Rosen. Chronic cough due to bronchiectasis: ACCP evidence-based clinical practice guidelines. , 2006, Chest.
[60] A. O'donnell,et al. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. , 1998, Chest.